Major Depressive Disorder

FDA Endorses CaaMTech's Psilocin Drug Development For Depression Treatment

Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression

Beckley Psytech Doses First Patients With Psilocin In Trial For Treatment Of Major Depression Disorder

Cybin Inc. Begins Phase 3 Trials, Betting Big On CYB003 To Treat Depression

Beckley Psytech Doses First Patients With Psilocin In Trial For Treatment Of Major Depression Disorder

LSD Microdosing For Depression? This Clinical Study Reveals Promising Results

Single Dose Of Cybin's Psilocybin Shows Compelling Patient Outcomes, Phase 2 Results Find

LSD Microdosing For Depression? This Clinical Study Reveals Promising Results

Single Dose Of Cybin's Psilocybin Shows Compelling Patient Outcomes, Phase 2 Results Find

Cybin Completes Dosing In Phase 2 Study Of CYB003 For Major Depressive Disorder Treatment

Depression Relief: Possible Therapy Boost With DMT & SSRIs, Per Small Pharma Clinical Results

Major Depressive Disorder Recent News

Cybin Delivers Highest Dose Of Psilocybin Analog In Phase 2 For Major Depression

Clinical-stage psychedelics biotech Cybin (NYSE: CYBN) has completed enrollment in its Phase 2 study of novel deuterated psilocybin analog CYB003 for the potential treatment of Major Depressive Disorder (MDD.)

Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, New Usona Phase 2 Trial Shows

Nonprofit medical research organization the Usona Institute shared the results from its Phase 2 trial assessing a single 25mg synthetic psilocybin dose for 104 adults with Major Depressive Disorder (MDD,) providing further evidence of the psychedelic’s

Trial On DMT Drug For Anxiety And Depression Ends Participant Dosing, Study Results Soon Released

Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug CYB004.

80 Years Post-Discovery, LSD Shows Significant Potential For Major Depression In Advanced Clinical Trial

Psychedelics biopharma company Mind Medicine Inc.’s (NASDAQ: MNMD) shared positive topline data from an advanced clinical trial evaluating its lysergide (aka LSD) for the treatment of Major Depressive Disorder (MDD) on Friday — just a couple of days before the 80th anniversary of the discov

Psilocybin Therapy Continues To Show Positive Outcomes For Cancer And Major Depression Disorder

Results from an advanced clinical trial assessing psilocybin-assisted therapy for patients with cancer and Major Depressive Disorder (MDD) conducted by oncology center Sunstone Therapies were published in the acclaimed JAMA Oncology.

Could DMT Therapy Be The Future Of Brain Injury Treatment? This Study Has Promising Results

Short-acting psychedelics company Small Pharma Inc.

FSD Pharma's Australian Entity To Proceed With Phase I Trial For Major Depressive Disorder

Biotech company FSD Pharma Inc. (NASDAQ: HUGE)’s Australian business FSD Pharma Australia Pty Ltd. has been approved by the Alfred Ethics Committee to begin a Phase 1 clinical trial of next-gen drug candidate Lucid-201, or Lucid-Psych, for cases of Major Depressive Disorder (MDD.)

Small Pharma Inc: Positive Clinical Data For Major Depressive Disorder, Upcoming Virtual Roundtable

Short-acting psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) shared positive outcomes from its Phase 2a study of SPL026, the first placebo-controlled trial of the DMT-based short-duration psychedelic compound for the treatment of Major Depressive Disorder (MDD).

Israeli Biotech Develops Ketamine Analogue To Treat Major Depression With Promising Results

Israeli-based psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) and partners Bar-Ilan University and Professor Gal Yadid from the Gonda Multidisciplinary Brain Research Center have obtained positive results from the latest preclinical trial on a next-gen psychedelic for the treatment of Major

Small Pharma, Inc's Psychedelics For Major Depression Trial Results And Q1 Earnings

Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF)’s proprietary intravenous (IV) DMT-based drug SPL026 delivered positive topline results in a Phase 2a trial for the treatment of Major Depressive Disorder (MDD).

This IV Psychedelic-Based Compound Completes Phase 2a Trial, Company Gets Extra IP Coverage

Short-acting psychedelics biotech company Small Pharma Inc.

Analyzing Psychedelics & Traditional Pharma Interaction: New Clinical Trial Begins Dosing

Psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) confirmed that the first patient has been dosed in its Phase 1b study assessing the interaction between selective serotonin reuptake inhibitors (SSRIs) and proprietary lead DMT candidate SPL026 in patients with Major Depressive Disorder (MDD).

FDA Green Lights New Study Testing IV Ketamine Infusion For Depressive Disorder

After a full review of healthcare provider Ehave Inc.'s (OTC Pink: EHVVF) IND application, the U.S.

Relmada Stock Tumbles To 52-Week Low On Failed Depression Trial

Mindset Pharma Meets With UK Regulator: Is A Phase 1 Trial Getting Close?

Biotech drug discovery firm Mindset Pharma Inc.

Cybin Announces First Dosing In Human Trial With Proprietary Psychedelic Drug For Depression

New Zealand Government Grants $650K For LSD Microdosing Trials

Mindbio Therapeutics, a subsidiary of cannabis and psychedelics holding company Blackhawk Growth Corp.

How To Enroll In A Psychedelic Clinical Trial In 5 Easy Steps

This article was originally published on Psychedelic Spotlight and appears here with permission. If you fail to meet even one of the inclusion criteria, or you meet even one of the exclusion criteria, then you are not eligible and you will not be selected for participation.

Study Finds Psilocybin Anti-Depression Effects Last At Least One Year

This article was originally published on Psychedelic Spotlight and appears here with permission.

Sage Therapeutics - Biogen Share One Year Zuranolone 50mg Data In Depression Patients

Sage Therapeutics Inc (NASDAQ: SAGE) and Biogen Inc (NASDAQ: BIIB) have

AbbVie's Major Depressive Disorder Candidate Shows Mixed Result In Late-Stage Trials

B. Riley Sees 'Significant Potential' In This Beaten-Up Biotech Stock

B. Riley analyst calls Seelos Therapeutics Inc (NASDAQ: SEEL) his top "Battered Bastions" pick with the stock down 60% from intra-year highs.

Sage Therapeutics - Biogen's Zuranolone Tops Placebo In Reducing Depressive Symptoms